The Hypoparathyroidism drugs in development market research report provides comprehensive information on the therapeutics under development for Hypoparathyroidism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hypoparathyroidism. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hypoparathyroidism and features dormant and discontinued products.
GlobalData tracks 14 drugs in development for Hypoparathyroidism by 16 companies/universities/institutes. The top development phase for Hypoparathyroidism is preclinical with four drugs in that stage. The Hypoparathyroidism pipeline has 14 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Hypoparathyroidism pipeline products market are: Entera Bio, OPKO Biologics and Shandong Buchang Pharmaceutical.
The key targets in the Hypoparathyroidism pipeline products market include Parathyroid Hormone/Parathyroid Hormone Related Peptide Receptor, Parathyroid Hormone Receptor, and Parathyroid Hormone.
The key mechanisms of action in the Hypoparathyroidism pipeline product include Parathyroid Hormone/Parathyroid Hormone Related Peptide Receptor Agonist with seven drugs in Phase III. The Hypoparathyroidism pipeline products include four routes of administration with the top ROA being Subcutaneous and five key molecule types in the Hypoparathyroidism pipeline products market including Recombinant Peptide, and Synthetic Peptide.
Hypoparathyroidism overview
Hypoparathyroidism is decreased function of the parathyroid glands with underproduction of parathyroid hormone. This leads to low levels of calcium in the blood, often causing cramping and twitching of muscles (involuntary muscle contraction) and several other symptoms. The condition can be inherited, but it is also encountered after thyroid or parathyroid gland surgery, and it can be caused by immune system-related damage as well as a number of rarer causes. The treatment includes an artificial form of the hormone that can be administered as replacement, calcium replacement, or vitamins.
For a complete picture of Hypoparathyroidism’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
